NSE: PEL | BSE: 500302

Mid-range Performer

Download real time

1072.20 -4.70 (-0.44%)

26.40% Gain from 52W Low

315.3K NSE+BSE Volume

NSE 09 Sep, 2025 3:48 PM (IST)

24,304.4

Market Cap

High in industry

1.5

Beta 1Year

Very High Volatility

Piramal Enterprises Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for PEL, BSE:500302 Piramal Enterprises Ltd.

Piramal Enterprises Ltd.

09 Feb 2023, 12:00AM

1072.20

-0.44%

One-off gains lead to strong earnings despite elevated credit costs

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

Piramal Enterprises .. has an average target of 1250.00 from 1 broker.

Piramal Enterprises Ltd.

10 Nov 2022

1072.20

-0.44%

Disappoints again; surge in stress recognition spikes provisioning

Buy: Piramal Enterprises Ltd.

Target

ICICI Securities Limited

Piramal Enterprises (PEL) once again disappointed, reporting a loss of Rs15bn in Q2FY23, as it provided Rs33bn (>5% of AUM) primarily towards wholesale portfolio.

Number of FII/FPI investors increased from 251 to 267 in Jun 2025 qtr.

Piramal Enterprises Ltd.

10 Nov 2022

1072.20

-0.44%

Stressed pool recognition in Wholesale led to elevated credit costs

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

Piramal Enterprises Ltd. is trading below all available SMAs

Piramal Enterprises Ltd.

15 Sep 2022

1072.20

-0.44%

Building out the Retail franchise in the NBFC entity

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

Piramal Enterprises .. has an average target of 1250.00 from 1 broker.

Piramal Enterprises Ltd.

01 Sep 2022

1072.20

-0.44%

Financial services business price discovery; goes ex- pharma a day prior to record date

Buy: Piramal Enterprises Ltd.

ICICI Securities Limited

Piramal Enterprises (PEL) has fixed September 1, ‘22 as demerger of Piramal Pharma record date.

Number of FII/FPI investors increased from 251 to 267 in Jun 2025 qtr.

Piramal Enterprises Ltd.

31 Jul 2022

1072.20

-0.44%

Retail gaining momentum, slippages continue in Wholesale; intermittent constraints in Pharma

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

Piramal Enterprises .. has an average target of 1250.00 from 1 broker.

Piramal Enterprises Ltd.

27 May 2022

1072.20

-0.44%

Elevated provisions and interest income reversals in FS; Pharma EBITDA margin below our estimate

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

Number of FII/FPI investors increased from 251 to 267 in Jun 2025 qtr.

Piramal Enterprises Ltd.

11 Feb 2022

1072.20

-0.44%

DHFL integration progressing well; good show in Pharma despite industry headwinds

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

Piramal Enterprises (PIEL) reported a healthy 3QFY22 result, characterized by various factors. a) 44% QoQ growth in retail disbursements exhibited momentum and will continue to improve hereon b) GNPA/NNPA increased just 40bp/30bp QoQ to 3.3%/1.8%, driven by one slippage in the Wholesale segment and the impact of the RBI NPA circular and yet PIEL delivered net provision write-backs. c) The focus was on execution, resulting in steady progress on the articulated strategy and the DHFL integration. d) Ten live fintech and consumer-tech partnerships are evolving well and contributed 96%...

Number of FII/FPI investors increased from 251 to 267 in Jun 2025 qtr.

Piramal Enterprises Ltd.

12 Nov 2021

1072.20

-0.44%

Positioning itself as a large Retail HFC; Pharma margin would improve in 2HFY22

Buy: Piramal Enterprises Ltd.

Motilal Oswal

PIEL reported a consolidated PAT of INR4.3b, down 32% YoY and 20% QoQ. This was driven by a decline in Financial Services' (FS) revenue, led by a reduction in the Wholesale loan book. This was also in part because of extra-ordinary expenses of INR1.53b on the DHFL acquisition and the...

Number of FII/FPI investors increased from 251 to 267 in Jun 2025 qtr.

Piramal Enterprises Ltd.

08 Oct 2021, 12:00AM

1072.20

-0.44%

Pharma demerger: Value unlocking underway

Buy: Piramal Enterprises Ltd.

Target

Motilal Oswal

PIEL's board approved the simplification of its corporate structure by creating two separate listed entities in Financial and Pharmaceutical Services, subject to shareholder, creditor, and regulatory approvals. The demerger would optimize the capital structure for each business and enable both to independently pursue growth opportunities. We remain positive on PIEL on the back of: a) its fully integrated CDMO presence, b) niche portfolio, with global distribution in the Complex Hospital Generics (CHG) space, c) strong brands with an established pan-India distribution network, d)...

Number of FII/FPI investors increased from 251 to 267 in Jun 2025 qtr.

Is Piramal Enterprises Ltd. worth buying?

796 Votes:

Buy 74.87%

Sell 15.7%

Hold 9.42%

RESEARCH REPORTS

Neutral SEE REPORTS >

pdf

Neutral SEE REPORTS >

pdf